Abstract 30P
Background
Accelerated partial breast irradiation (APBI) is now widely adopted in the treatment with low risk early breast cancer worldwide. Both stereotactic body radiotherapy (SBRT) using Cyberknife (CK) and interstitial brachytherapy (IB) are available for APBI. This study was designed to compare the dosimetric characteristics of organ at risk and the clinical outcome between two different techniques.
Methods
Forty-four patients with left sided early breast cancer treated by APBI in our institute were reviewed. The radiation doses are 30Gy in 5 fractions, in 5 consecutive days using CK and 34Gy in 10 fractions, BID in 5 consecutive days using IB. Dosimetric parameters of OARs were calculated for both techniques and compared. The preliminary clinical outcomes include the local recurrence rate, acute toxicity (CTCAE V5.0) and cosmetic evaluation (Harvard scales) were analyzed.
Results
The median follow up time of CK group and IB group were 19.3 months (range: 4.5∼48.4 months) and 53.5months, respectively. Two patients from IB group had sentinel lymph node micrometastasis in the final pathology report and whole breast irradiation plus regional lymph node irradiation was added subsequently. One patient from IB group had regional lymph node recurrence during follow up and underwent surgery and re-irradiation with stable disease now. Most common acute toxicity was grade 1 radiation dermatitis. Neither radiation pneumonitis nor heart events were noted during the follow up. Multiple small scars left for more than 6 months in a few patients after interstitial brachytherapy. Patients reported cosmetic results according to Harvard scales, with “good” score in most patient of IB group and no cases described as “poor”. Dosimetric parameters of OAR showed the heartV150cGy of CK and IB was 23.5% and 59.2%. The mean heart dose of CK and IB were 117.1cGy and 215.6cGy.
Conclusions
APBI by SBRT using CK is a non-invasive procedure and has better dose-sparing effect on the heart. There were less risks of wound infection or delayed wound healing when using CK. Since no small scars left on the breast when using CK, better cosmetic outcome is expected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract
39P - Prognostic significance of hypoxic microenvironment biomarkers in invasive ductal breast cancer
Presenter: Sungmin Kang
Session: Poster Display
Resources:
Abstract